| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 28.01 | 1.32 (+4.95%) | 11.21 - 29.92 | 134.1 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 26.91 |
|---|---|
| Previous Close | 26.69 |
| Day's Range | 26.89 - 28.17 |
| Market Cap | 566.8M |
| Avg Volume (10 Day) | 190.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | 0.01 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV
Business Wire - Tuesday 05/14/2013 8:30 AM ET
Ligand Reports First Quarter Financial Results
Business Wire - Wednesday 05/08/2013 4:00 PM ET
Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
Business Wire - Tuesday 04/30/2013 5:50 AM ET
Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
PR Newswire - Tuesday 04/30/2013 5:50 AM ET
Ligand Presents Preclinical Data on HepDirect™ Liver-Targeting Technology Platform at 2013 International Liver Congress (EASL) Annual Meeting
Business Wire - Friday 04/26/2013 8:30 AM ET
Ligand to Present at Upcoming Investor Conferences
Business Wire - Tuesday 04/23/2013 9:00 AM ET
Ligand to Report First Quarter Results on May 8th
Business Wire - Monday 04/22/2013 9:00 AM ET
| LGND | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 17.71% | |
| Net Income Growth (1yr) | -95.30% | |
| Total Debt/Equity | 0.88 | |
| LT Debt/Equity | 0.35 | |
| Earnings Yield | -- | |
| Price/Sales | 15.15 |
| Company | Last | Change |
|---|---|---|
| Avanir Pharmaceuticals Inc | 3.32 | +0.61% |
| Sagent Pharmaceuticals Inc | 16.28 | +2.13% |
| Momenta Pharmaceuticals Inc | 13.03 | -0.08% |
| Hi-Tech Pharmacal Co Inc | 32.27 | +2.64% |
| Supernus Pharmaceuticals Inc | 6.00 | +2.74% |
Data is delayed by at least 15 min.